Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study

Jensterle,Mojca; Goricar,Katja; Janez,Andrej

doi:10.3892/etm.2016.3081

Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study

Authors:
- Mojca Jensterle
- Katja Goricar
- Andrej Janez
View Affiliations

Affiliations: Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre, SI‑1000 Ljubljana, Slovenia, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, SI‑1000 Ljubljana, Slovenia
Published online on: February 16, 2016 https://doi.org/10.3892/etm.2016.3081
Pages: 1194-1200
Copyright: © Jensterle et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liraglutide (LIRA) treatment is associated with the dose-dependent reduction of weight. Higher doses are more effective than lower doses, although higher doses are also more poorly tolerated. Metformin may enhance the weight-lowering potential of LIRA via the stimulatory modulation of incretin in addition to its direct beneficial effects in PCOS. The aim of the present study was to evaluate whether metformin as an adjunct to low‑dose LIRA affects body weight with increased efficacy compared with low‑dose LIRA alone in obese patients with PCOS. In a 12‑week study, 44 obese women with PCOS were randomly offered either combined treatment (COMBO) with 1,000 mg metformin twice a day and 1.2 mg LIRA once a day, or treatment with 1.2 mg LIRA alone. The primary outcome of treatment was an alteration in the levels of obesity. A total of 43 patients [aged 30.3±4.4 years; body mass index (BMI) 37.2±4.5 kg/m2; mean ± standard deviation] completed the study. The subjects treated with COMBO lost on average 6.2±2.4 kg compared with a 3.8±3.5 kg weight loss in the patients treated with LIRA alone (P=0.024). The BMI decreased by 2.2±0.8 kg/m2 in patients treated with COMBO and by 1.4±1.2 kg/m2 in patients treated with LIRA alone (P=0.024). A clinically significant ≥5% weight reduction was achieved in 59.1% of patients treated with COMBO and 42.9% of patients treated with LIRA alone. Reductions in glucose levels following oral glucose tolerance testing, as well as in androstenedione levels in the COMBO group were significantly greater compared with those in the LIRA group. The side effects were mild and transient in the two treatment groups. A combination of metformin and low‑dose LIRA was more effective than low-dose LIRA alone in reducing body weight in obese patients with PCOS.

View Figures

View References

1	Lim SS, Davies MJ, Norman RJ and Moran LJ: Overweight, obesity and central obesity in women with polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod Update. 18:618–637. 2012. View Article : Google Scholar : PubMed/NCBI
2	Pasquali R: Obesity and androgens: Facts and perspectives. Fertil Steril. 85:1319–1340. 2006. View Article : Google Scholar : PubMed/NCBI
3	Cattrall FR and Healy DL: Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 18:803–812. 2004. View Article : Google Scholar : PubMed/NCBI
4	Lass N, Kleber M, Winkel K, Wunsch R and Reinehr T: Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome and intima-media thickness in obese adolescent girls. J Clin Endocrinol Metab. 96:3533–3540. 2011. View Article : Google Scholar : PubMed/NCBI
5	Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A and Ragni G: Overweight and obese anovulatory patients with polycystic ovaries: Parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod. 18:1928–1932. 2003. View Article : Google Scholar : PubMed/NCBI
6	Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ and Brinkworth GD: The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile and reproductive function in overweight and obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 93:3373–3380. 2008. View Article : Google Scholar : PubMed/NCBI
7	Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R and Welt CK: Endocrine Society: Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 98:4565–4592. 2013. View Article : Google Scholar : PubMed/NCBI
8	Vilsbøll T, Christensen M, Junker AE, Knop FK and Gluud LL: Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials. BMJ. 344:d77712012. View Article : Google Scholar : PubMed/NCBI
9	Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF and Lean ME: NN8022-1807 Study Group: Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet. 374:1606–1616. 2009. View Article : Google Scholar : PubMed/NCBI
10	Lean ME, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rössner S, Van Gaal L and Astrup A: NN8022-1807 Investigators: Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond). 38:689–697. 2014. View Article : Google Scholar : PubMed/NCBI
11	Jensterle M, Kravos NA, Pfeifer M, Kocjan T and Janez A: A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens). 14:81–90. 2015.PubMed/NCBI
12	Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA and Janez A: Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 170:451–459. 2014. View Article : Google Scholar : PubMed/NCBI
13	Bruno RV, de Avila MA, Neves FB, Nardi AE, Crespo CM and Sobrinho AT: Comparison of two doses of metformin (2.5 and 1.5 g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference. Fertil Steril. 88:510–512. 2007. View Article : Google Scholar : PubMed/NCBI
14	Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C, Pagotto U and Pasquali R: Treatment with flutamide, metformin and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: A randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab. 91:3970–3980. 2006. View Article : Google Scholar : PubMed/NCBI
15	Harborne LR, Sattar N, Norman JE and Fleming R: Metformin and weight loss in obese women with polycystic ovary syndrome: Comparison of doses. J Clin Endocrinol Metab. 90:4593–4598. 2005. View Article : Google Scholar : PubMed/NCBI
16	Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P and Norman RJ: Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: Systematic review and meta-analysis. Hum Reprod Update. 15:57–68. 2009. View Article : Google Scholar : PubMed/NCBI
17	Maida A, Lamont BJ, Cao X and Drucker DJ: Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia. 54:339–349. 2011. View Article : Google Scholar : PubMed/NCBI
18	Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Messeri G and Rotella CM: Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 24:489–494. 2001. View Article : Google Scholar : PubMed/NCBI
19	Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S, Pezzatini A, Brogi M, Dicembrini I and Cremasco F: Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab. 17:336–342. 2004.PubMed/NCBI
20	Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T and Tanaka I: Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun. 298:779–784. 2002. View Article : Google Scholar : PubMed/NCBI
21	American Diabetes Association: Standards of medical care in diabetes-2013. Diabetes Care. 36(Suppl 1): S11–S66. 2013.PubMed/NCBI
22	Moran LJ, Pasquali R, Teede HJ, Hoeger KM and Norman RJ: Treatment of obesity in polycystic ovary syndrome: A position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril. 92:1966–1982. 2009. View Article : Google Scholar : PubMed/NCBI
23	Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:412–419. 1985. View Article : Google Scholar : PubMed/NCBI
24	Dupont WD and Plummer WD Jr: Power and sample size calculations. A review and computer program. Control Clin Trials. 11:116–128. 1990. View Article : Google Scholar : PubMed/NCBI
25	Alberti KGI, Zimmet P and Shaw J: Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 23:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
26	Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D and Bhushan R: Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 93:2670–2678. 2008. View Article : Google Scholar : PubMed/NCBI
27	Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR and Shulman GI: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 49:2063–2069. 2000. View Article : Google Scholar : PubMed/NCBI
28	Palomba S, Falbo A, Zullo F and Orio F Jr: Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: A comprehensive review. Endocr Rev. 30:1–50. 2009. View Article : Google Scholar : PubMed/NCBI
29	Davies MJ, Kela R and Khunti K: Liraglutide-overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab. 13:207–220. 2011. View Article : Google Scholar : PubMed/NCBI